Showing 231-240 of 5833 results for "".
First Cell-Based Gene Therapy for RDEB
https://practicaldermatology.com/series/dermwire-tv/first-cell-based-gene-therapy-for-rdeb/35742/In this week's DermwireTV, the FDA approves the first cell-based gene therapy for recessive dystophic epidermolysis bullosa (RDEB); a new acne scar treatment using focal point technology is cleared in the US; and in our “Updates on Skin Cancer” feature, we hear about the advantages of 40-GEP testingHow Incyte Is Following the Science to Address Unmet Needs in Immune-Mediated Skin Conditions
https://practicaldermatology.com/topics/infections-infectious-disease/how-incyte-is-following-the-science-to-address-unmet-needs-in-immune-mediated-skin-conditions/19945/Ahmad Naim, MD, Vice President of US Medical Affairs at Incyte, shares how the company’s discovery expertise in immunology is fueling research aimed at delivering innovative medicines that address the unmet needs of people living with immune-mediated dermatologic conditions, including atopic dermatiCosmetic Surgery Forum News: CSF Moves to Nashville!
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/cosmetic-surgery-forum-news-csf-moves-to-nashville/20795/They don't call it Nash-Vegas for nothing. CSF is moving east but keeping all the key features.First, Do No Harm
https://practicaldermatology.com/conferences/scale-2023/first-do-no-harm/20206/Joel L. Cohen, MD, and Mathew M. Avram, MD, JD, discuss why dermatologists should report any side effects to the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database.How Incyte Is Following the Science to Develop Innovative Solutions for Immune-Mediated Skin Conditions
https://practicaldermatology.com/topics/atopic-dermatitis/how-incyte-is-following-the-science-to-develop-innovative-solutions-for-immune-mediated-skin-conditions/20158/Jim Lee, head of the Inflammation and Autoimmunity clinical development group at Incyte, discusses the role of the immune system in atopic dermatitis (AD) and vitiligo and shares how Incyte is following the science to develop innovative options impacting the lives of people with these conditions.UV Avoidance: Fostering Adherence in Youth and Adults
https://practicaldermatology.com/topics/skin-cancer-photoprotection/uv-avoidance-fostering-adherence-in-youth-and-adults/23503/With a bit of forethought, dermatologists can help change patient behaviors for the long term.Update on COVID-19 Vaccines and Dermal Fillers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/update-on-covid-19-vaccines-and-dermal-fillers/23451/CSF faculty discuss risks of delayed facial swelling in filler patients following COVID-19 vaccination.DermWireTV: Clinical Support Tech Data; Dupixent, Stelara Updates; Rihanna Launches Fenty Skin
https://practicaldermatology.com/topics/psoriasis/dermwiretv-clinical-support-tech-data-dupixent-stelara-updates-rihanna-launches-fenty-skin/19835/A feasibility study in collaboration between LEO Innovation Lab, VisualDX, and the German Association of Dermatological Prevention supports technology to assist in diagnosis of skin conditions. Leo Pharma’s investigational JAK inhibitor delgocitinib cream is Fast Tracked by the FDA for the potentiaTopical Tretinoin: A Versatile Option for Adult Female Acne
https://practicaldermatology.com/issues/supplements/topical-tretinoin-a-versatileoption-for-adult-female-acne/23042/Findings of a roundtable discussion with leading acne experts on the benefits of retinoids for acne patients.Expanded Indications for UltraClear Cold Ablative Fractional Fiber Laser
https://practicaldermatology.com/series/c-suite-chats/expanded-indications-ultraclear-cold-ablative-fractional-fiber-laser/26268/Shlomo Assa, President and Co-Founder of Acclaro Medical, discusses the versatility of the UltraClear Cold Ablative Fractional Fiber Laser, which recently received FDA clearance to treat benign pigmented lesions and vascular dyschromia.